Discussion

SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical (human and aquaculture), cosmetic, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge-exchange.
SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep sea oligotrophic basins of the Eastern Mediterranean Sea and unsampled areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds.

Authors
RuAngelie Edrada-Ebel1, Lynsey MacIntyre1, Mariana Fazenda1, Tong Zhang1, Carol Clements2, Louise Young2, Grainne Abbott2, Linda Harvey1, Alan Harvey2¬¬ & Brian McNeil1
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, Scotland, United Kingdom.
2 Strathclyde Innovations in Drug Research (S.I.D.R), University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, Scotland, United Kingdom.